Industry Trends

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.

The pharma industry is beginning to perform better with environmental, social, and governance (ESG).

How one company in particular has adjusted its internal and customer-facing strategies in compliance training amid today’s heightened business-risk climate.

Major stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.

Pharma companies may benefit from meeting challenges and embracing small molecule drug discovery.

Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.

Corrigan discusses the importance of a patient-centric approach.

Outlook for orphan PRMA environment in the US, EU4, and UK.

Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.

Round discusses how he adjusted his leadership style and approach to patient care in the most effective way during the pandemic.

DiMambro discusses how companies can update their systems and strategies to collect data which ensures that marginalized groups and diverse voices are included.

Ford discusses how rising drug costs in impact patients, and how they can either avoid them or find less-expensive options.

Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.

Industry must continue research and development to combat the pandemic.

Flesch speaks with Pharm Exec about his work to bring a patient-centric approach to the forefront of the industry.

Investments setting up sector for future success that could one day rival its US counterpart.

COVID-19 pandemic has accelerated raised expectations for medical information professionals.

Moorman discusses critical aspects of key account management in pharma.

While patients continue to benefit from increased product launches, the pandemic is still having an impact on caseload.

Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Pandemic workforce trends continue to create challenges for pharma.

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.

Upcoming regulatory changes to create new opportunity for specialized offerings.

Industry has shown it can overcome challenges en route to creating new therapies.

Rise in demand for sustainable practices forces industry to be more proactive.

Hill shares her insights on what is needed for a turnaround in talent development.

New mediums of technology must be utilized correctly to reap full benefits.

New regulations set stage for updated ESG considerations.